Hepatocellular carcinoma (HCC) is the third-leading cause of cancerrelated mortality worldwide. Most cases of HCC are associated with cirrhosis from various causes such as alcohol or viral hepatitis. Most patients are symptomatic as a result of cirrhosis itself or secondary to tumor extension. These tumors have an affinity for the vasculature and often invade the portal system. HCC rarely causes invasion of the inferior vena cava or the heart. We, however, present a case of HCC in a patient without cirrhosis who remained asymptomatic despite having tumor extension to the heart by way of the inferior vena cava. The mean survival in patients with intracardiac extension with or without aggressive treatment or intervention is approximately 4 months, but our patient greatly exceeded survival expectations after treatment with sorafenib.
H epatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is often associated with cirrhosis of the liver. Th ese tumors are quite vascular. We present a case of a patient without known cirrhosis who presented with intracardiac extension of HCC inferior vena cava invasion.
CASE PRESENTATION
A 76-year-old white man with hypertension, asymptomatic carotid disease, and type II diabetes mellitus presented for routine follow-up. He was asymptomatic. His social history was negative for alcohol use, tattoos, travel, illicit drug use, blood transfusions, or chemical exposures in the past. His body mass index was 27 kg/m 2 . Examination disclosed no scleral icterus, ascites, organomegaly, asterixis, or spider angiomata. Complete blood counts, basic chemistries, bilirubin, albumin, and coagulation studies were normal. Table 1 notes additional studies.
Abdominal ultrasound revealed an 8 cm right hepatic lobe mass. A triple-phase computed tomography (CT) scan of the abdomen revealed a 12 × 8 cm hepatic mass and inferior vena cava compression, but no evidence of cirrhosis (Figure 1 ). Repeat CT 1 month later revealed an 11 × 13 cm mass with inferior vena cava tumor infi ltration and extension to the right atrium, where a 4 × 4 cm mass consistent with tumor infi ltration was noted (Figure 2 ). Liver biopsy noted some hepatocytes with mild fatty changes and no evidence of hemosiderosis or cirrhosis, consistent with moderately diff erentiated HCC. An echocardiogram showed an ejection fraction of 55% to 60% and a 2.5 × 2.5 cm fi xed mass in the right atrium.
Th e patient was started on sorafenib. He tolerated treatment well with only minimal side eff ects, such as hand-foot syndrome, for approximately 10 months after the diagnosis. He later developed fatigue, dyspnea, and weight loss. Repeat CT noted disease progression. He died approximately 14 months after diagnosis.
DISCUSSION
HCC has a 5-year survival of 5% in nontransplant candidates (1-3) . Approximately 80% of cases worldwide are attributable to viral hepatitis (4). Nonviral factors that lead to HCC include obesity and diabetes mellitus (causing nonalcoholic fatty liver disease). Alcohol abuse and tobacco use, hemochromatosis, oral contraceptives, afl atoxin, pesticides, and cirrhosis of any cause can also cause HCC (1-3) are symptomatic and occur in older adults, whereas cirrhotic patients with HCC may be relatively asymptomatic (5) . HCC often metastasizes to lymph nodes, bone, and lung, but it also has a signifi cant tendency for vascular invasion (6) . Tumor extension to the portal system is quite common, but invasion of the inferior vena cava and/or heart without invasion of the portal system is rare (incidence 0.53%; 6% at autopsy) (4, 5) . Local invasion is more common in cirrhotic patients (5). In the rare cases of HCC with tumor extension to the right atrium and inferior vena cava, most patients were either symptomatic, had cirrhosis, or both (4) (5) (6) (7) (8) (9) .
Th e mean survival in HCC patients with inferior vena cava or right atrium extension is 1 to 4 months regardless of treatment (4, 7). Th ere may be a modest benefi t with radiation, transarterial chemoembolization, or systemic chemotherapy with sorafenib, depending on the size of the lesions (6). Palliative cardiac surgery can be used in cases of cardiac obstruction (8, 9) .
In recent years, HCC has been treated with sorafenib, an oral chemotherapeutic agent that targets several tyrosine kinase-dependent molecular pathways, such as vascular endothelial growth factor and platelet-derived growth factor-beta. Th ese pathways allow for proliferation of HCC; therefore, sorafenib has been associated with reduced angiogenesis and increased apoptosis of tumor cells in HCC. Th e SHARP (Sorafenib HCC Assessment Randomized Protocol) trial randomized patients with advanced HCC who were Child-Pugh Class A and had good performance scores (Eastern Cooperative Oncology Group scores of 2 or less) to sorafenib versus placebo. Th ere was an increase in overall survival of approximately 3 months in the sorafenib-treated group (median survival of 10.7 months in the treated group compared with 7.9 months in the placebo group) with only minimal side eff ects of hypertension, hand-foot syndrome, hypertension, and diarrhea (10) .
To our knowledge, this is the fi rst patient without evidence of viral hepatitis or cirrhosis to present asymptomatically with HCC and cardiac involvement. Our case is also unique in that the etiology of this patient's HCC remains largely cryptogenic. Most importantly, our patient greatly exceeded survival expectations based on currently reported survival data of patients with extensive intracardiac tumor burden (the median survival is 4 months, and our patient survived >14 months). It should be noted, however, that most of the available survival data regarding intracardiac HCC did not involve patients treated with sorafenib. Our patient's increased survival further underscores the importance of targeted chemotherapeutic agents such as sorafenib in the treatment of patients with advanced HCC. 
